Valuation
Is the price right?Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.
Bringing the fundamentals into focus…
Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026
Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.
2/3 inputs reported · Partial data
Stronger than most peers on:
Revenue and earnings-per-share growth over one year, and revenue growth over three years.
2/3 inputs reported · Partial data
Mixed versus peers:
Return on invested capital, operating margin, and return on assets.
3/3 inputs reported · High confidence
Weaker than most peers on:
Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Valuations in Healthcare are within their usual range since 2016.
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.
Price history is added with the daily price update and will appear after the next one.